Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer

Asian Journal of Andrology

Volumn 13, Issue 5, 2011, Pages 683-689

  Pal, Sumanta Kumar ^a   Sartor, Oliver ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

abiraterone; bevacizumab; cabazitaxel; castrate resistant; castration resistant; docetaxel; hormone refractory; Jevtana; prostate cancer; Provenge; sipuleucel T

Indexed keywords

ABIRATERONE; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; DOCETAXEL; ESTRAMUSTINE; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROVENGE; SATRAPLATIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 80052466157     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.35     Document Type: Review

References (75)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. US Mortality Data, 1960-2006, US Mortality Vol. 1930-1959. Atlanta, GA: National Center for Health Statistics, Centers for Disease Control and Prevention.
3. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-52.
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
5. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D et al.Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
6. TM. Urol Oncol 2006; 24: 396-402.
7. Bolla M, de Reijke TM, van Tienhoven G, van den Bergh AC, Oddens J et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
8. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
9. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
10. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13.
11. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
12. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
13. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
14. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
15. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94.
16. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9.
17. BLA Teleconference Summary-Provenge, June 26. 2007. http://www.fda.gov/ downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ UCM213982.pdf (accessed 29 November 2010).
18. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
19. Provenge Approval Letter. http://www.fda.gov/BiologicsBloodVaccines/ CellularGene TherapyProducts/ApprovedProducts/ucm210215.htm (accessed 29 November 2010).
20. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20.
21. Sheikh NA, Wesley JD, Chadwick E, Perdue N, de Rosa CP et al. Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T. J Clin Oncol 2011; 29: Abstr 155.
22. Bissery MC, Bouchard H, Riou J, Vrignaud P, Combeau C et al. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res 2000; 41: Abstr 1364.
23. Mita AC, Denis LJ, Rowinsky EK, DeBono JS, Goetz AD et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723-30.
24. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
25. Pal SK, Sartor AO. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010; 5: 395-402.
26. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
27. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-23.
28. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007; 12: 4957-71.
29. Eisenberger M, O'Dwyer P, Friedman M. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 1986; 4: 414-24.
30. Scher H, Liebertz C, Kelly W, Mazumdar M, Brett C, Schwartz L et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928-38.
31. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005; 96: 1241-6.
32. Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997; 62: 133-42.
33. Attard G, Reid AHM, A'Hern R, Parker C, Oommen NB et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.
34. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501.
35. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95.
36. Ryan C, Efstathiou E, Smith M, Taplin M, Bubley G et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 2009; 27: abstr 5046.
37. de Bono JS, Logothetis C, Fizazi K, North S, Chu L et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase 3 study. Proceedings of the 35th European Society for Medical Oncology (ESMO) Congress; 11 October 2010; Milan, Italy. ESMO: Lugano, Switzerland, 2010. Abstract Number: LBA5
38. NCT00887198: Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. http://www.clinicaltrials.gov (accessed 29 July 2009).
39. NCT01023061: Phase II trial of radiation with androgen deprivation (RAD): abiraterone acetate, prednisone and LHRH agonist prior to and concurrent with radiation therapy. http://www.clinicaltrials.gov (accessed 15 October 2010).
40. NCT00924469: A phase 2 open-label, randomized, multi-center study of neoadjuvant abiraterone acetate (CB7630) plus leuprolide acetate and prednisone versus leuprolide acetate alone in men with localized high risk prostate cancer. http://ww.clinicaltrials.gov (accessed 15 October 2010).
41. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010; 28: abstr LBA4511.
42. Scher HI, Chi KN, de Wit R, Berry WR, Albers P et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from the phase III ASCENT2 trial. J Clin Oncol 2010; 28: 4509.
43. AstraZeneca Website. Results of zibotentan phase III trial in castration resistant prostate cancer. http://www.astrazeneca.com/Media/Press-releases/ Article/Results-of-Zibotentan-Phase-III-trial-in-castration-resistant-pr (accessed 2 December 2010).
44. NCT00617669: A phase III trial of ZD4054 (zibotentan) (endothelin a antagonist) and docetaxel in metastatic hormone resistant prostate cancer (ENTHUSE M1C). http://www.clinicaltrials.gov (accessed 2 December 2010).
45. NCT00134056: Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer. http://www.clinicaltrials.gov (accessed 2 December 2010).
46. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-66.
47. Glinsky GV. Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study. Clin Cancer Res 2009; 15: 1504-5.
48. Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res 2010; 16: 5269-76.
49. Mathew P, Tannir N, Tu S, Carter C, Bekele N et al. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 2010; 65: 811-5.
50. Taneja SS. Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancer. Curr Urol Rep 2009; 10: 4-5.
51. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247-54.
52. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005; 4: 259-74.
53. Higano C, Saad F, Somer B, Curti B, Petrylak D et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Proceeding of the 2009 Genitourinary Cancers Symposium; 26 February 2009; Orlando, FL, USA. ASCO: Alexandria, VA, USA, 2009, Abstr LBA150.
54. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7.
55. Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proceeding of the 2009 Genitourinary Cancers Symposium; 26 February 2009; Orlando, FL, USA. ASCO: Alexandria, VA, USA, 2009, Abstr 7.
56. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL et al. Overall survival analysis of a phase ii randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-105.
57. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
58. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46.
59. NCT01212991: A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). http://www. clinicaltrials.gov (accessed 29 November 2010).
60. NCT00974311: AFFIRM: a multinational phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of oral MDV3100 in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. http://www.clinicaltrials.gov (accessed 15 October 2010).
61. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. JSteroid Biochem Mol Biol; e-pub ahead of print 17 November 2010; doi: 10.1016/j. jsbmb.2010.11.005.
62. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study. J Clin Oncol 2010; 28: abstr 3084.
63. NCT01193257: Study comparing orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer. http://www.clinicaltrials.gov (accessed 2 December 2010).
64. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 2008; 101 (Suppl 2): 11-5.
65. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-65.
66. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
67. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.
68. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-7.
69. Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006; 24: 2828-35.
70. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654-63.
71. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 2003; 21: 490-5.
72. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 940-5.
73. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22: 1025-33.
74. Berry WR, Hathorn JW, Dakhil SR, Loesch DM, Jackson DV et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 2004; 3: 104-11.
75. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T etal. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8.